The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro and Zepbound, to add safety warnings about a potential increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious condition that can lead to sudden, painless loss of vision in one eye, including permanent vision loss.
The FDA announced the decision on Monday. Its assessment included an analysis of 126 clinical trials involving over 134,000 patients, alongside real-world data and published observational studies. The agency acknowledged limitations in the available evidence but concluded that a potential increased risk warranted additional warnings across the entire drug class.
The new requirements cover all GLP-1 receptor agonists, a class of medicines widely used to treat type 2 diabetes and obesity. Popular treatments include Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound.
The move adds to the safety scrutiny surrounding a rapidly expanding class of medicines that has become central to the treatment of obesity and type 2 diabetes. Last year, Europe's medicines watchdog (EMA) determined that NAION should be classified as a very rare side effect of semaglutide, the active ingredient in some weight-loss medicines, affecting up to one in 10,000 patients.
Analysis
Why This Matters
- Millions of patients taking GLP-1 drugs for diabetes or weight loss now face a newly highlighted risk of a rare but potentially blinding eye condition, which may affect prescribing decisions and patient consent.
- The FDA's class-wide warning, covering all GLP-1 receptor agonists, not just semaglutide, expands the safety concern beyond what Europe's EMA identified last year, potentially triggering global regulatory reviews.
- The ruling signals increased regulatory vigilance around one of the most commercially successful drug classes, with implications for manufacturers' liability and future clinical trials.
Background
GLP-1 receptor agonists were originally developed to treat type 2 diabetes and have become widely prescribed for weight loss. NAION (non-arteritic anterior ischaemic optic neuropathy) is a rare condition that damages the optic nerve, leading to sudden vision loss. The FDA reviewed evidence from clinical trials, real-world data and observational studies before issuing the warning.
Key Perspectives
- FDA: concluded that a potential increased risk of NAION warranted additional warnings across the drug class, though it acknowledged limitations in the available evidence.
- European Medicines Agency (EMA): last year classified NAION as a very rare side effect of semaglutide, affecting up to one in 10,000 patients.
What to Watch
- Whether other national regulators, including the UK's MHRA and Australia's TGA, review their own safety labels for GLP-1 drugs.
- Manufacturers' responses: they may update patient information leaflets and could face legal claims related to the newly disclosed risk.
- Future studies: the FDA's acknowledgment of evidence limitations suggests further research into the GLP-1–NAION link may be forthcoming, potentially refining risk estimates or identifying predisposed patients.
Checked
11 claims in this story checked against 1 source: 11 supported.
Show each claim
- SupportedThe FDA is requiring safety warnings on GLP-1 drugs over a potential risk of vision loss.Euronews: “The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to update their safety labels to warn of a potential increased risk of a rare but serious eye condition that can cause permanent vision loss.”
- SupportedThe FDA says popular GLP-1 drugs are associated with a potential increased risk of a rare but serious eye condition.Euronews: “The US drug watchdog FDA on Monday said the weight-loss drugs had been associated with non-arteritic anterior ischaemic optic neuropathy (NAION)”
- SupportedThe warning applies to GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro and Zepbound.Euronews: “The new warning requirements cover all GLP-1 receptor agonists, a class of medicines widely used to treat type 2 diabetes and obesity. They include popular treatments such as Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound”
- SupportedNAION can cause sudden, painless loss of vision in one eye, including permanent vision loss.Euronews: “a condition that can lead to sudden, painless loss of vision in one eye, including permanent vision loss.”
- SupportedThe FDA announced the decision on Monday.Euronews: “The US drug watchdog FDA on Monday said the weight-loss drugs had been associated with non-arteritic anterior ischaemic optic neuropathy (NAION)”
- SupportedThe FDA assessment included 126 clinical trials involving over 134,000 patients.Euronews: “The FDA's assessment included an analysis of 126 clinical trials involving over 134,000 patients.”
- SupportedThe FDA also reviewed real-world data and published observational studies.Euronews: “The agency also reviewed real-world data and published observational studies.”
- SupportedThe FDA acknowledged limitations in the evidence but concluded that a potential increased risk warranted warnings across the drug class.Euronews: “While it acknowledged limitations in the available evidence, it concluded that a potential increased risk warranted additional warnings across the drug class.”
- SupportedGLP-1 medicines are widely used to treat type 2 diabetes and obesity.Euronews: “a class of medicines widely used to treat type 2 diabetes and obesity.”
- SupportedThe move adds to safety scrutiny around a rapidly expanding class of medicines central to treating obesity and type 2 diabetes.Euronews: “The move adds to the safety scrutiny surrounding a rapidly expanding class of medicines that has become central to the treatment of obesity and type 2 diabetes.”
- SupportedLast year, the EMA determined NAION should be classified as a very rare side effect of semaglutide, affecting up to one in 10,000 patients.Euronews: “Last year, Europe’s medicines watchdog (EMA) determined that NAION should be classified as a very rare side effect of semaglutide, the active ingredient of some weight-loss medicines, affecting up to one in 10,000 patients.”